**Appendix A:** Data Extraction Form.

**Summary Data**

|  |  |
| --- | --- |
| Reviewer name |   |
| Date form completed |   |

**Trial Unique Identifier**

e.g. Smith1999a

|  |
| --- |
|   |

**Source**

|  |  |
| --- | --- |
| Year of publication |   |
| Journal |   |
| PUBMED ID |   |
| Institutional sponsor and/or data custodian |   |
| Corresponding author(if different to above) |   |

 **Methods (Bias)**

|  |  |
| --- | --- |
| Trial Registration ID |   |
| Study design |   |
| Total study duration |   |
| Sequence generation |   |
| Allocation sequenceconcealment |   |
| Blinding |   |
| Completeness of outcome data |   |
| Selective reporting |   |
| Other concerns about bias |   |

 **Participants**

|  |  |
| --- | --- |
| Total number |  |
| Country |   |
| Setting |   |
| Inclusion criteria |   |
| Exclusion criteria |   |
| Withdrawals/exclusions |   |
| Diagnostic criteria ofcoma |   |
| Age |   |
| Sex | Males |
| Methods of recruitment |   |
| Average length of fever |   |
| Seizures |   |
| Type of seizure | Tonic clonic |   |
| Focal |   |
| Lactate |   |
| BCS (or equivalent coma score) on admission |   |
| Retinopathy |   |
| EEG |   |
| Cerebral imaging |   |
| HIV status | Proportion tested |   |
|   | Proportion unknown |   |
| Proportion HIV+ |   |
| CD4 count |   |
|   | Proportion exposed |   |
| HIV ART treatment | Proportion on ART |   |
| Nutrition status | Proportion with malnutrition |   |
|   |   |
|   | Proportion with SAMProportion with wasting |   |
| Proportion with wasting |   |
| Proportion with stunting |   |
| Admission details | Delay to hospital presentation |   |
|   | Time from admission to diagnosis |   |
|   | Time from admission to discharge |   |
|   | Duration of coma prior to admission |   |
|   | Depth of coma prior to admission |   |
| Other comorbidities |   |   |
| Other subgroups reported |   |   |

**Interventions (for RCT studies)**

|  |  |
| --- | --- |
| Number ofintervention groups |   |
|   | Regimen 1 | Regimen 2 | Regimen 3 |
| Intervention e.g. drug type |   |   |   |
| Number randomised to group |   |   |   |
| Duration of treatment period |   |   |   |
| Timing |   |   |   |
| Delivery |   |   |   |
| Providers |   |   |   |
| Co-interventions |   |   |   |

 **Outcomes**

**Aetiology**

|  |  |  |
| --- | --- | --- |
| Details of microbiological methods | *Microbiological microscopy and culture* |   |
| *Molecular (PCR)* |   |
| *Type of PCR (single or multiplex)* |   |
| *Other (e.g. metagenomic sequencing* |   |
| Details of antimicrobial resistance testing |   |
| % of culture positive cases |   |
| % of culture negative cases |   |
| **1 Aetiology****Syndrome proportion****e.g. ABM % of total cohort**        | Cerebral Malaria |   |
| CM with co-infection |   |
| ABM |   |
| Encephalitis |   |
| Sepsis |   |
| Unknown Encephalopathy |   |
| Non-infective Encephalopathy |   |
| Other (group) |   |
| Specify other if listed e.g. neurocysticercosis) |   |
| Other 1 |   |
| Other 2 |   |
| Other 3 |   |
| **2 Aetiology****pathogen proportion per syndrome e.g. Strep Pneumo % of total ABM (for all syndromes e.g. ABM, encephalitis etc)**                  | **Cerebral Malaria** |   |
| CM with co-infection (list pathogens) |   |
| **ABM** |   |
| Strep Pneumoniae |   |
| Salmonella spp (include type if available) |   |
| N. Meningitidis |   |
| H. Influenzae |   |
| E. coli |   |
| Klebsiella |   |
| Acinetobacter |   |
| Other |   |
| **Encephalitis** |   |
| HSV1 |   |
| HSV2 |   |
| CMV |   |
| VZV |   |
| Enterovirus |   |
| Other |   |
| **Sepsis** |   |
| Staphylococcal aureus |   |
| N. Meningitidis |   |
| H. Influenzae |   |
| E. coli |   |
| Klebsiella |   |
| Acinetobacter |   |
| **Unknown Encephalopathy** |   |
| **Other (group)** |   |
| Specify other if listed e.g. neurocysticercosis |   |
| Other 1 |   |
| Other 2 |   |
| Other 3 |   |

**Clinical Outcome**

**Outcomes**

Notes:

For interventional studies, the outcomes in the usual care arm of the study only were included

|  |  |  |
| --- | --- | --- |
| Outcome measures used | Neurological Sequelae |   |
| Death |   |
| Other (e.g. neurocognitive assessments) |   |
| *Please specify:* |
| Duration of follow-up |   |

**Disability**

|  |  |
| --- | --- |
| **1 disability proportion in entire cohort e.g. 35% had neurological sequelae** |   |

|  |  |  |
| --- | --- | --- |
|  **Outcome 2 disability proportion in each syndrome e.g. 35% had neurological sequelae in ABM** | Cerebral Malaria |   |
| CM with co-infection |   |
| ABM |   |
| Encephalitis |   |
| Sepsis |   |
| Unknown Encephalopathy |   |
| Other (group) |   |
|   | Specify other if listed e.g. neurocysticercosis) |   |
| Other 1 |   |
| Other 2 |   |
|   | Other 3 |   |

|  |  |  |
| --- | --- | --- |
| **Outcome 3 Disability proportion in each pathogen e.g. 35% had neurological sequelae with Strep Pneumo**                      | **Cerebral Malaria** |   |
| CM with co-infection (list pathogens) |   |
| **ABM** |   |
| Strep Pneumoniae |   |
| Salmonella spp (include type if available) |   |
| N. Meningitidis |   |
| H. Influenzae |   |
| E. coli |   |
| Klebsiella |   |
| Acinetobacter |   |
| Other |   |
| **Encephalitis** |   |
| HSV1 |   |
| HSV2 |   |
| CMV |   |
| VZV |   |
| Enterovirus |   |
| Other |   |
| **Sepsis** |   |
| N. Meningitidis |   |
| H. Influenzae |   |
| E. coli |   |
| Klebsiella |   |
| Acinetobacter |   |
| **Unknown Encephalopathy** |   |
| **Other (group)** |   |
| Specify other if listed e.g. neurocysticercosis) |   |
| Other 1 |   |
| Other 2 |   |
| Other 3 |   |

|  |  |  |  |
| --- | --- | --- | --- |
| **Outcome 4 - Proportion of disability type per clinical diagnosis e.g. %age ABM patients with deafness**   | Cerebral Malaria | *Motor**Cognitive/behavioural**Visual impairment**Hearing impairment**Epilepsy* |   |
| CM with co-infection | *Motor**Cognitive/behavioural**Visual impairment**Hearing impairment**Epilepsy* |   |
| ABM | *Motor**Cognitive/behavioural**Visual impairment**Hearing impairment**Epilepsy* |   |
| Encephalitis | *Motor**Cognitive/behavioural**Visual impairment**Hearing impairment**Epilepsy* |   |
| Sepsis | *Motor**Cognitive/behavioural**Visual impairment**Hearing impairment**Epilepsy* |   |
| Unknown Encephalopathy | *Motor**Cognitive/behavioural**Visual impairment**Hearing impairment**Epilepsy* |   |
| Other (group) | *Motor**Cognitive/behavioural**Visual impairment**Hearing impairment**Epilepsy* |   |
| Specify other if listed e.g. neurocysticercosis) |   |   |
| Other 1 |   |   |
| Other 2 |   |   |
| Other 3 |   |   |

**Death**

|  |  |
| --- | --- |
| **Outcome 1 Death proportion in entire cohort e.g. 35% died** |   |

|  |  |  |
| --- | --- | --- |
| **Outcome 2 death proportion in each syndrome e.g. 35% died in ABM** | Cerebral Malaria |   |
| CM with co-infection |   |
| ABM |   |
| Encephalitis |   |
| Sepsis |   |
| Unknown Encephalopathy |   |
| Other (group) |   |
| Specify other if listed e.g. neurocysticercosis) |   |
| Other 1 |   |
| Other 2 |   |
| Other 3 |   |

|  |  |  |
| --- | --- | --- |
| **Outcome 3 Death proportion in each pathogen e.g.** 35% of those with Strep Pneumo ABM died                      | **Cerebral Malaria** |   |
| CM with co-infection (list pathogens) |   |
| **ABM** |   |
| Strep Pneumonia |   |
| Salmonella spp (include type if available) |   |
| N. Meningitidis |   |
| H. Influenzae |   |
| E. coli |   |
| Klebsiella |   |
| Acinetobacter |   |
| Other |   |
| **Encephalitis** |   |
| HSV1 |   |
| HSV2 |   |
| CMV |   |
| VZV |   |
| Enterovirus |   |
| Other |   |
| **Sepsis** |   |
| Staphylococcal aureus |   |
| N. Meningitidis |   |
| H. Influenzae |   |
| E. coli |   |
| Klebsiella |   |
| Acinetobacter |   |
| **Unknown Encephalopathy** |   |
| **Other (group)** |   |
| Specify other if listed e.g. neurocysticercosis) |   |
| Other 1 |   |
| Other 2 |   |
| Other 3 |   |

**Other Information**

|  |  |
| --- | --- |
| Comments on statistical methods |   |
| Have important populations been excluded from the study? |   |
| Key conclusions of study authors |   |
| Funding source |   |